Neuroleptic malignant syndrome

British Journal of Hospital Medicine

Volumn 55, Issue 8, 1996, Pages 517-520

  Bristow, M F ^a   Kohen, D ^b  

^a EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; HUMAN; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE ANTAGONISTS; HUMANS; MENTAL DISORDERS; NEUROLEPTIC MALIGNANT SYNDROME; RECEPTORS, DOPAMINE; RISK FACTORS;

EID: 0030591243     PISSN: 00071064     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Addonizio G, Susman V, Roth SD (1986) Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am JPsychiatry 143: 1587-90
2. Adityanjee SS (1991) The spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 158: 706-7
3. Caroff SN, Mann SC (1993) The neuroleptic malignant syndrome. Med Clin North Am 77: 185-202
4. Deng MZ, Chen GQ, Phillips MR (1990) Neuroleptic malignant syndrome in 12 out of 9792 Chinese inpatients exposed to neuroleptics. Am J Psychiatry 147: 1149-55
5. Guerrera RJ, Chang SS, Romcro JA (1992) A comparison of diagnostic criteria for neuroleptic malignant syndrome./ Clin Psychiatry 53: 56-62
6. Keck P, Pope H, Cohen BM et al (1989) Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 46:914-18
7. Nishijima K, Ishiguro T (1990) Neuroleptic malignant syndrome: a study of CSF monoamine metaBolism. Biol Psychiatry 27: 280-8
8. O'Dwyer A-M, Sheppard N (1993) The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. Psycho! Med 23: 323-6
9. Osman A A, Khursani M (1994) Lethal catatonia and neuroleptic malignant syndrome -a dopamine receptor shut-down hypothesis. Br J Psychiatry 165: 548-50
10. Parada MA, de Parada MP, Rada P, Hernandez L (1995) An animal model for the neuroleptic malignant syndrome. Brain Res 674(1): 117-21
11. Raja M, Altavista M, Cavallari S et al (1994) Neuroleptic malignant syndrome and catatonia. Eur Arch Psychiatry Clin Neurosci 243: 299-303
12. Rosebush P, Stewart T (1989) A prospective analysis of 24 episodes of neuroleptic malignant syndrome Am J Psychiatry 146: 717-25
13. Rosebush P Stewart T Gelenberg L (1989) Twenty neuroleptic rechallenges after fifteen cases of NMS. J Clin Psychiatry 50: 295-8
14. Sewell D, Jeste D (1992) Distinguishing NMS from NMS like acute medical illnesses. / Neuropsychiatr Clin Neurosci 4: 265-9
15. Shalev A, Hermesh H, Munitz H (1989) Mortality from neuroleptic malignant syndrome. / Clinic Psychiatry 50: 18-25
16. Velamoor V, Norman RMG, Caroff SN et al (1994) Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 182: 168-73
17. White DAC, Robins AH (1991) Catalonia-harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 158:419-21
18. White DAC (1992) Catatonia and the neuroleptic malignant syndrome -a single entity? Br J Psychiatry 161: 558-60